Structure-based programming of lymph-node targeting in molecular vaccines

Nature

Volumn 507, Issue 7493, 2014, Pages 519-522

  Liu, Haipeng ^a,b   Moynihan, Kelly D ^a,b   Zheng, Yiran ^a,b   Szeto, Gregory L ^a,b   Li, Adrienne V ^a,b   Huang, Bonnie ^a,b   Van Egeren, Debra S ^b   Park, Clara ^a   Irvine, Darrell J ^a,b,c  

^a Massachusetts Institute of Technology Cambridge   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOPHILE; VACCINE;

ANTIGEN; DISEASE CONTROL; DRUG PRESCRIBING; MOLECULAR ANALYSIS; TOXICITY; TUMOR; VACCINE;

ANIMAL EXPERIMENT; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; LIPOPHILICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SENTINEL LYMPH NODE; T LYMPHOCYTE;

MUS;

ANIMALS; BASE SEQUENCE; CPG ISLANDS; FEMALE; LYMPH NODES; MICE; MICE, INBRED C57BL; T-LYMPHOCYTES; VACCINES, SUBUNIT; VACCINES, SYNTHETIC;

EID: 84897954314     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature12978     Document Type: Article

References (28)

1. Salhab, M., Patani, N.&Mokbel, K.Sentinel lymph nodemicrometastasis inhuman breast cancer: an update. Surg. Oncol. 20, e195-e206 (2011).
2. Tsopelas, C. & Sutton, R. Why certain dyes are useful for localizing the sentinel lymph node. J. Nucl. Med. 43, 1377-1382 (2002).
3. Johansen,P., Mohanan, D.,Martínez-Gómez, J.M.,Kündig,T.M.&Gander,B. Lymphogeographical concepts in vaccine delivery. J. Control. Release 148, 56-62 (2010).
4. Moon, J. J., Huang, B. & Irvine, D. J. Engineering nano-and microparticles to tune immunity. Adv. Mater. 24, 3724-3746 (2012).
5. Gupta, R. K. Aluminum compounds as vaccine adjuvants. Adv. Drug Deliv. Rev. 32, 155-172 (1998).
6. Bachmann, M. F. & Jennings, G. T. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nature Rev. Immunol. 10, 787-796 (2010).
7. Hubbell, J. A., Thomas, S. N. & Swartz, M. A. Materials engineering for immunomodulation. Nature 462, 449-460 (2009).
8. De Temmerman, M. L. et al. Particulate vaccines: on the quest for optimal delivery and immune response. Drug Discov. Today 16, 569-582 (2011).
9. Pal, I. & Ramsey, J. D. The role of the lymphatic system in vaccine trafficking and immune response. Adv. Drug Deliv. Rev. 63, 909-922 (2011).
10. Reddy, S. T. et al. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nature Biotechnol. 25, 1159-1164 (2007).
11. St John, A. L., Chan, C. Y., Staats, H. F., Leong, K. W. & Abraham, N. A. Synthetic mast-cell granules as adjuvants to promote and polarize immunity in lymph nodes. Nature Mater. 11, 250-257 (2012).
12. Trubetskoy, V. S. & Torchilin, V. P. Use of polyoxyethylene-lipid conjugates as longcirculating carriers for delivery of therapeutic and diagnostic agents. Adv. Drug Deliv. Rev. 16, 311-320 (1995).
13. Keler, T., He, L., Ramakrishna, V. & Champion, B. Antibody-targeted vaccines. Oncogene 26, 3758-3767 (2007).
14. Tenbusch, M. et al. Immunogenicity of DNA vaccines encoding simian immunodeficiency virus antigen targeted to dendritic cells in rhesus macaques. PLoS ONE 7, e39038 (2012).
15. Faries, M. B. et al.Activemacromoleculeuptake by lymph node antigen-presenting cells: a novel mechanism in determining sentinel lymph node status. Ann. Surg. Oncol. 7, 98-105 (2000).
16. Schaafsma, B. E. et al. The clinical use of indocyanine green as a near-infrared fluorescent contrast agent for image-guided oncologic surgery. J. Surg. Oncol. 104, 323-332 (2011).
17. Vollmer, J. & Krieg, A. M. Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. Adv. Drug Deliv. Rev. 61, 195-204 (2009).
18. Bode, C., Zhao, G., Steinhagen, F., Kinjo, T. & Klinman, D. M. CpG DNA as a vaccine adjuvant. Expert Rev. Vaccines 10, 499-511 (2011).
19. Liu, H., Kwong, B. & Irvine, D. J. Membrane anchored immunostimulatory oligonucleotides for in vivo cellmodification andlocalizedimmunotherapy. Angew. Chem. Int. Ed. Engl. 50, 7052-7055 (2011).
20. Krieg, A. M. & Stein, C. A. Phosphorothioate oligodeoxynucleotides: antisense or anti-protein? Antisense Res. Dev. 5, 241 (1995).
21. Bourquin,C. et al. TargetingCpGoligonucleotides to the lymphnodeby nanoparticles elicits efficient antitumoral immunity. J. Immunol. 181, 2990-2998 (2008).
22. Zeng, W.,Ghosh,S., Lau, Y. F., Brown, L. E.&Jackson, D. C. Highlyimmunogenic and totally synthetic lipopeptides as self-adjuvanting immunocontraceptive vaccines. J. Immunol. 169, 4905-4912 (2002).
23. Kastantin, M. et al. Thermodynamic and kinetic stability of DSPE-PEG(2000) micelles in the presence of bovine serum albumin. J. Phys. Chem. B 114, 12632-12640 (2010).
24. Peters, T. All About Albumin: Biochemistry, Genetics, and Medical Applications (Academic, 1995).
25. Barouch, D. H. et al. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J. Immunol. 172, 6290-6297 (2004).
26. Schreurs, M. W. et al. Dendritic cells break tolerance and induce protective immunity against a melanocyte differentiation antigen in an autologous melanoma model. Cancer Res. 60, 6995-7001 (2000).
27. Feltkamp, M. C. et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur. J. Immunol. 23, 2242-2249 (1993).
28. Kenter, G. G. et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N. Engl. J. Med. 361, 1838-1847 (2009).